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Meningococcus serogroup C clonal 
complex ST-10217 outbreak in 
Zamfara State, Northern Nigeria
Brenda A. Kwambana-Adams1, Rahab C. Amaza2, Catherine Okoi1, Murtala Rabiu  3,  
Archibald Worwui1, Ebenezer Foster-Nyarko1, Bernard Ebruke1, Abdul K. Sesay1, 
Madikay Senghore1, Abdullahi S. Umar4, Rabi Usman4, Adamu Atiku4, Garba Abdullahi2, 
Yahaya Buhari3, Rabiu Sani3, Husaini U. Bako3, Bashir Abdullahi3, Alliyu I. Yarima3, Badaru Sikiru2, 
Aderinola Olaolu Moses2, Michael O. Popoola2, Eme Ekeng2, Adebola Olayinka2, Nwando Mba2, 
Adamu Kankia6, Ibrahim N. Mamadu6, Ifeanyi Okudo6, Mary Stephen6, Olivier Ronveaux7, 
Jason Busuttil8, Jason M. Mwenda9, Mohammed Abdulaziz5, Sulaiman A. Gummi4, 
Adebayo Adedeji2, Andre Bita10, Linda Omar9, Mamoudou Harouna Djingarey9, 
Wondimagegnehu Alemu6, Umberto D’Alessandro  11, Chikwe Ihekweazu2 & Martin Antonio1,12
After the successful roll out of MenAfriVac, Nigeria has experienced sequential meningitis outbreaks 
attributed to meningococcus serogroup C (NmC). Zamfara State in North-western Nigeria recently was 
at the epicentre of the largest NmC outbreak in the 21st Century with 7,140 suspected meningitis cases 
and 553 deaths reported between December 2016 and May 2017. The overall attack rate was 155 per 
100,000 population and children 5–14 years accounted for 47% (3,369/7,140) of suspected cases. The 
case fatality rate (CFR) among children 5–9 years was 10%, double that reported among adults ≥ 30 
years (5%). NmC and pneumococcus accounted for 94% (172/184) and 5% (9/184) of the laboratory-
confirmed cases, respectively. The sequenced NmC belonged to the ST-10217 clonal complex (CC). 
All serotyped pneumococci were PCV10 serotypes. The emergence of NmC ST-10217 CC outbreaks 
threatens the public health gains made by MenAfriVac, which calls for an urgent strategic action against 
meningitis outbreaks.
The “meningitis belt” spans twenty-six contiguous countries across Africa and is characterized by large recur-
rent meningitis epidemics and frequent seasonal outbreaks1. Within the “meningitis belt”, Neisseria meningitidis 
(meningococcus) accounts for almost all recurrent epidemics. The entire northern region of sub-Saharan Africa’s 
most populous country, Nigeria, falls within the meningitis belt. Nigeria has a long history of large-scale meningi-
tis outbreaks dating as far as the early 1900s; in 1921, an outbreak in northern Nigeria caused 46,000 deaths2. The 
most recent largest meningitis outbreak occurred in 1996, with over 80,000 suspected cases3,4.
The bulk of epidemic meningococcal disease outbreaks in Nigeria and across the “meningitis belt” were previ-
ously attributed to meningococcus serogroup A (NmA)5. MenAfriVac is a conjugate vaccine that is very immuno-
genic and, provides effective protection against NmA6. MenAfriVac campaigns have prevented NmA epidemics 
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and reduced the incidence of suspected meningitis by nearly two-thirds7. In 2011, nearly 16 million people in five 
high priority states (Zamfara, Katsina, Jigawa Bauchi and Gombe) in northern Nigeria received MenAfriVac8.
In 1975, Nigeria experienced a large NmC epidemic associated with relatively high rates of meningococcaemia 
and high case fatality rates as seen in the recent outbreaks2,9. Before 2013, the latest outbreak of NmC in Africa 
had occurred in 1979 in Burkina Faso10. Sequential outbreaks of meningococcus serogroup C (NmC) occurred 
in Nigeria in 2013 and 2014 in Nigeria11,12 despite the roll out of MenAfriVac campaigns. These outbreaks were 
followed by a larger outbreak in Niger in 201513. All the recent outbreaks were attributed to a novel strain of NmC 
sequence type (ST)-10217 whose emergence threatens the public health gains made by the MenAfriVac14–16.
Monovalent (C) and quadrivalent (A,C,W,Y) formulations of the meningococcal conjugate vaccine are availa-
ble and The World Health Organization (WHO) recommends that countries with endemic or frequent epidemics 
of meningococcal disease should implement large-scale vaccination campaigns17,18. However, the rollout of vac-
cines that protect against NmC has been slow and tends to be reactive during outbreaks. The major constraints 
to preventive vaccination campaigns include high vaccine cost, limited vaccine availability and competing public 
health interests15. During epidemics, reactive vaccination campaigns are further hampered by low lumbar punc-
ture rates among suspected cases and inadequate laboratory characterisation of causative pathogens that should 
guide response19.
Between December 2016 and May 2017, a total of 14,280 suspected meningitis cases were reported across 23 
of the 36 states in Nigeria. The descriptive characterization of the 2016–2017 cerebrospinal meningitis outbreak in 
Nigeria is reported elsewhere20. There were 1,145 deaths (8% case fatality rate) amongst suspected cases. Zamfara 
and Sokoto states were at the epicenter of the meningitis epidemic in Nigeria. The World Health Organization 
Collaborating Center (WHO CC) for New Vaccines hosted at the Medical Research Council Unit The Gambia 
at London School of Hygiene & Tropical Medicine, supports surveillance of invasive bacterial diseases (IBD) 
in West and Central Africa. The WHO CC with its partners, supported the Nigeria Center for Disease Control 
(NCDC) to confirm the causative agent of the outbreak in Zamfara state. The WHO CC also trained and sup-
ported the laboratory teams at regional and district hospitals in Zamfara for bacteriologic analysis and processing 
of CSF specimens for molecular analysis.
Results
A total of 7,140 suspected meningitis cases were reported in Zamfara State between 12th December 2016 and 31st 
May 2017. The attack rate was 155 per 100,000 population. A total of 553 deaths were reported among suspected 
cases and the case fatality ratio (CFR) was 8% in Zamfara state.
CSF specimens were collected from 404 (6%) suspected meningitis cases and almost all, 383 (95%), had at 
least one or all laboratory tests performed including bacteriologic culture, Gram stain, Rapid Test (Pastorex) and 
qPCR. The laboratory processing of CSF specimens is shown in Fig. 1. A pathogen was detected in 184 (48%) of 
the CSF specimens tested by PCR, rapid test and culture. Meningococcus was the dominant pathogen accounting 
for 173 (94%) of the confirmed cases. The characteristics of the suspected and confirmed meningitis cases are 
summarised in Table 1. Of the 112 CSF specimens tested by both PCR and Rapid Test, the concordance was 86 
(77%). PCR detected an additional 19 Nm meningitis cases in addition to the 22 cases detected by both methods 
and 3 cases detected by Rapid Test only.
NmC accounted for 172 (99%) of the meningococci detected. There was one case of meningococcus serogroup 
W (NmW) meningitis detected by latex rapid test. MLST performed directly from two CSF specimens that tested 
positive for NmC showed that they belonged to the ST-10217 CC. Unfortunately, the meningococcal isolates 
cultured from CSF specimens during the outbreak were lost due to the lack of appropriate storage conditions in 
Zamfara state. It was not possible to perform MLST on more NmC positive CSF specimens due to the limited 
availability of funds.
Streptococcus pneumoniae, the pneumococcus, accounted for 9 (5%) cases. All five of the serotyped pneumo-
cocci were PCV10 vaccine strains; three were serotype 19 F strains, one serotype 1 and one serotype 5. There were 
also single cases of confirmed Group B Streptococcus (GBS) and H. influenzae.
Figure 1. Summary of CSF specimen collection and processing in Zamfara State.
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Spatial and temporal characteristics of the outbreak. The epicentre of the outbreak in Zamfara state 
(Fig. 2A) was Shinkafi Local Government Area (LGA), which had an attack rate of 669 per 100,000 population 
and bore a fifth of all the suspected cases (Fig. 2B). Other LGAs with high attack rates were Bakura and Birnin 
Magaji, which had 210 and 255 suspected cases per 100,000 population, respectively. Gusau, the state capital, 
accounted for 12% of the suspected cases reported, although many of these suspected cases may have been refer-
rals from other LGAs (Fig. 2B). Shinkafi, Maradun and Gusau had the highest confirmed cases, over 8 per 100,000 
population. Meningococcus was the dominant pathogen across all the LGAs in Zamfara state. Pneumococcal 
meningitis was reported in Bakura, Gusau, Magaji and Bimiri (Fig. 2C).
Although Tsafe had a relatively low attack rate of 44.4 per 100,000, this LGA had the highest CFR of 17% 
(Fig. 2D). Other LGAs with high CFRs were Kaura Namoda (12%), Bukkuyum (13%) and Bakura (11%). 
Suspected meningitis cases from Tsafe LGA were more than three times likely to die compared to suspected 
meningitis cases from Gusau (p < 0.01) (Table 2). Likewise, suspected meningitis cases from Bakura and Kaura 
Namoda LGAs had significantly higher odds of dying than suspected meningitis cases from Gusau LGA (Table 2). 
Suspected meningitis cases from Maradun and Bungudu had CFRs less than 5% (Fig. 2D) and were significantly 
less likely to die than suspected from the state capital, Gusau.
The first suspected meningitis cases in Zamfara state occurred in December 2016 but were only reported 
at the national level in February 2017. By the 31st of May 2017 the number of cases had increased to 7140. The 
highest attack rates exceeding 20 per 100,000 population were reported between epidemiologic weeks 16 and 18 
(Fig. 3A). The bulk of the suspected meningitis cases 6,205 (86%) occurred between March and April 2017, which 
corresponds to the peak of hot dry harmattan winds.
Although fewer suspected cases were reported in the earlier weeks, the likelihood of death amongst suspected 
cases was highest then (Fig. 3B). Although the CFR declined to 10% or less after epidemiologic week 8, the abso-
lute number of deaths increased substantially over the following weeks as the total number of suspected cases also 
increased. Half the deaths among suspected cases in Zamfara state occurred between epidemiologic weeks 9 and 
12 (Fig. 3B). The odds of dying amongst suspected meningitis cases declined significantly over time (Table 2).
The first confirmed case was identified five weeks after the start of the outbreak, with meningococcus as the 
causing pathogen (Fig. 3C). All confirmed cases thereafter were attributed to meningococcus until the 17th week 
of the outbreak when pneumococcus, GBS and H. influenzae were detected. Most pneumococcal meningitis 
cases, 7 (77%) were reported between weeks 20 and 23 (Fig. 3C).
Demographic characteristics of the outbreak. Half of the suspected cases and 56% of the confirmed 
cases were males (Table 1). Male suspected cases died more frequently with a CFR of 8.7 compared to 6.8 among 
females. Males accounted for 311 (56%) of all deaths. Older children (5–14 years) and young adults (15–29 years 
old) accounted for 5,458 suspected cases, more than three-quarters of all suspected cases (Table 1). Older children 
between 5 and 14 years accounted for two-thirds (322/553) of the deaths reported. Likewise, the highest CFRs of 
9.7 and 9.3 were reported among children 5–9 and 10–14 years old, respectively (Fig. 4A). Adults (≥30 years old) 
had the lowest CFR (4%). Suspected meningitis cases between the ages of 5 and 14 years old were nearly twice 
as likely to die than adults older than 30 years old (P < 0.01) (Table 2). Two of the three confirmed meningitis 
cases among infants were attributed to pneumococcus. There was at least one case of pneumococcal meningitis 
in all the age groups, except among the 15–29 year olds (Fig. 4B). The only cases of H. influenzae and GBS were 
Characteristic Category Suspected Cases n (%)
Confirmed 
Cases n (%)
Gender
Female 3,566 (49.9%) 79 (42.7%)
Male 3,574 (50.1%) 106 (57.3%)
Age
<1 37 (0.5%) 3 (6.5%)
1–4 838 (11.7%) 17 (9.2%)
5–9 1,640 (23.0%) 52 (28.1%)
10–14 1,729 (24.2%) 58 (31.3%)
15–29 2,089 (29.3%) 42 (22.7%)
> = 30 803(11.3%) 12 (6.5%)
Unknown 4 (0.05%) 1 (0.5%)
On set month
December 17 (0.2%) 0 (0.0%)
January 180 (2.5%) 9 (4.9%)
February 340 (4.8%) 38 (20.5%)
March 2,174 (30.4%) 27 (14.6%)
April 4,031 (56.5%) 51 (27.6%)
May 353 (4.9%) 33 (17.8%)
Unknown 45 (0.6%) 27 (14.6%)
Outcome
Alive 6,553 (91.8%) 156 (84.2%)
Dead 553 (7.7%) 6 (3.2%)
Unknown 34 (0.5%) 23 (12.4%)
Table 1. Baseline characteristics of patients with suspected and confirmed meningitis in Zamfara State.
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reported in children aged 4 and 6 years. Two-thirds, of the confirmed meningococcus confirmed cases were 
among children between 5 and 14 years old (Fig. 4B).
Discussion
We report the largest NmC meningitis outbreak to hit a single state in Nigeria to date. Zamfara state in 
North-western Nigeria accounted for more than half of the 14,280 suspected meningitis cases reported across 
the country during the reported period of the outbreak20. This outbreak followed three previous outbreaks that 
occurred in North-western Nigeria after the successful MenAfriVac mass vaccination campaigns. Prior to the 
Figure 2. The geographical distribution of the meningitis outbreak in Zamfara State. The location of Zamfara 
state in Nigeria is shown in (A). Suspected cases per 100,000 population (B), laboratory-confirmed cases per 
100,000 population (C) and case fatality rates (D) across LGAs are shown by colour gradient. The pie charts 
represent the pathogens detected in confirmed cases (C).
Category Suspected Cases Deaths (%) OR 95%CI P-value
Age group (years) ≥30 802 39 (4.9) 1.00
<1 37 3 (8.1) 1.79 0.51–6.27 0.36
1–4 837 68 (8.1) 1.61 1.07–2.44 0.02
5–9 1633 160 (9.8) 1.94 1.35–2.8 <0.01
10–14 1714 162 (9.5) 1.85 1.28–2.67 <0.01
15–29 2080 121 (5.8) 1.19 0.82–1.72 0.37
*Sex Female 3550 242(6.8) 1.00 —
Male 3553 311(8.8) 1.16 0.97–1.39 0.10
Onset week 7103 0.87 0.85–0.89 <0.01
LGA Gusau 835 48(5.8) 1.00 —
Bakura 555 62(11.2) 1.91 1.28–2.84 <0.01
Birnin Magaji 643 36(5.6) 0.52 0.32–0.83 0.01
Bungudu 264 9(3.4) 0.48 0.23–0.99 0.05
Kaura Namoda 671 63(12.4) 1.62 1.10–2.37 0.01
Maradun 544 26(4.8) 0.50 0.30–0.83 0.01
Tsafe 167 29(17.4) 3.37 2.04–5.58 <0.01
Others 3424 260(7.6) 1.25 0.91–1.73 0.17
Table 2. Factors associated with mortality among suspected meningitis cases in Zamfara state. *Sex was 
included in the logistic regression model as a potential confounder with females as the reference. The reference 
for LGAs in the model was Gusau, the state Zamfara state capital. The reference for age group was adults >30 
years old.
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recent outbreaks, the last NmC outbreak in sub-Saharan Africa was reported in 1979 in Burkina Faso10. The 
emergence and expansion of NmC ST-10217 CC with the propensity to cause large outbreaks threatens the pub-
lic health gains made by the MenAfriVac campaigns7,16. This reinforces the need for strategic vision and action 
towards controlling meningitis epidemics in the meningitis belt.
Funk and colleagues reported NmC meningitis outbreaks that occurred sequentially in Sokoto (2013) and 
Kebbi (2014). These outbreaks were relatively small, with less than a thousand suspected cases and localised to 
specific regions in the affected states12. In 2015, larger outbreaks with 6,394 suspected cases were reported in 
Sokoto, Kebbi and Niger states11. Sidikou and colleagues also reported a large meningococcal meningitis out-
break with almost ten thousand suspected cases and 549 deaths in 201513. The 2016–2017 outbreak in Nigeria 
was much larger with 553 deaths in Zamfara state alone. All previous outbreaks were attributed to a novel strain 
of NmC ST-10217 CC. As with previous outbreaks, sequenced NmC also belonged to the ST-10217 CC. In 2016, 
NmC meningitis localised outbreaks were reported in Niger and Nigeria along with sporadic cases reported in 
Cote d’Ivore, Burkina Faso and Ghana21. Brynildsrud and colleagues performed whole-genome sequencing on 
150 meningococcal isolates collected during outbreaks in Nigeria and Niger between 2013 and 201716. Their 
analysis which included four NmC isolates collected from meningitis cases from Zamfara State in 2017 confirmed 
the dominance of ST-10217. Brynildsrud and colleagues demonstrated that this hypervirulent NmC ST-10217 
emerged through the acquisition of virulence factors and capsule genes16.
At a meeting on meningitis outbreak preparedness convened by WHO in 2015, global experts predicted that 
NmC outbreaks would continue to occur across the meningitis belt17. It may be possible that the current increase 
in NmC outbreaks is due to serogroup replacement following the mass MenAfriVac campaigns and this warrants 
further investigation. A key driver of this expansion is poor population immunity as carriage rates of NmC have 
historically been very low22. Furthermore, since the last NmC outbreak that occurred in the 20th Century, there 
have only been a few mass vaccination campaigns targeted at NmC17. This is further compounded by the emer-
gence of a novel virulent strain of NmC genetically distinct from previously described strains11,14. In light of this, 
the expansion in magnitude and spatial spread of NmC culminating in a large countrywide outbreak in Nigeria 
was predictable23.
There are several polysaccharide and conjugate vaccine formulations that include NmC. However, these vac-
cines have limited availability and are prohibitively expensive even at subsidized cost. The WHO currently rec-
ommends that the limited vaccine stocks be reserved for epidemics24. However, reactive vaccination is hugely 
dependent on strong and effective in-country surveillance systems with the capacity to rapidly and accurately 
detect, report and respond to meningitis outbreaks13. The revised WHO alert threshold is 3 confirmed cases per 
100,000 per week for meningitis24. Unfortunately, many countries in the meningitis belt, including Nigeria, have 
weak primary health care and national disease surveillance systems. The first cases of meningitis in Zamfara state 
Figure 3. Epidemiologic curve of the meningitis outbreak in Zamfara State. The attack rates (A), case fatality 
rates (B) and laboratory-confirmed cases (C) by epidemiologic week. The distribution of pathogens detected 
among laboratory-confirmed cases is shown in (C).
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occurred in December 2016 but only reported to the national level in February 2017. The NmC vaccination cam-
paigns did not start until April of 2017 at which point the outbreak had gone over its peak (Fig. 3).
One major constraint that delayed adequate and timely responses to the explosive meningitis outbreak was 
the lack of physicians to diagnose suspected meningitis cases and perform lumbar punctures. A small proportion, 
6% of the suspected meningitis cases had lumber puncture performed (Fig. 1). Another important challenge 
was the poor logistical support for specimen transport. In the few LGAs where the doctors were skilled enough 
to perform LPs, there were no systems in place for specimen transport to the microbiology laboratories. As a 
consequence, culture was performed on only a third of CSF specimens collected and the culture positivity was 
also low at 9%. The requisite TI transport media was not always available and most laboratories in this state did 
not have the capacity to detect and characterize bacterial agents of meningitis. Strengthening of national disease 
surveillance systems and laboratories is key in minimizing vaccine-preventable deaths due to meningococcal 
meningitis in the future.
In previous NmC outbreaks in northern Nigeria and Niger, the highest proportions of cases (39–48%) were 
among children 5 to 14 years old11–13. Likewise, in this outbreak, children 5 to 14 years old accounted for nearly 
half of suspected meningitis cases and for an even higher proportion (60%) of deaths. The CFR among children 
5 to 9 years old was 9.7, more than double the CFR among adults 30 years and older. These findings suggest that 
older children (5–14 years) may not only be more vulnerable to NmC meningitis but also more likely to die from 
it. WHO recommends vaccination of individuals 2–29 years during meningitis outbreaks17. However, targeted 
preventative mass vaccination campaigns for children 5–14 years in the most vulnerable communities may curtail 
NmC outbreaks and markedly reduce deaths.
An epidemiological curve similar to the 2015 Niger NmC outbreak13 was observed. The number of new sus-
pected meningitis cases remained relatively stable until the 15th week after which there was a sharp rise in new 
suspected cases. In contrast, outbreaks caused by NmA, NmW and NmX tend to increase steadily peaking earlier 
in the epidemic season19. Slow initial progression followed by rapid acceleration to the peak of the outbreak, 
towards the end of the epidemic season may be a unique feature of NmC outbreaks. This pattern reinforces the 
need to have in place adequate outbreak preparedness plans alongside stockpiling medical and laboratory sup-
plies including NmC-containing vaccines.
Figure 4. Case fatality rates and laboratory-confirmed cases by age group in Zamfara State. The case fatality 
rates and total suspected cases are shown by age group (A). The distribution of pathogens among laboratory-
confirmed cases by age-group (B). The suspected case counts by age group are presented in Table 1.
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All five serotyped pneumococci belonged to serotypes included in the 10-valent pneumococcal conjugate 
vaccine (PCV10) implemented in Nigeria. Large pneumococcal outbreaks have been reported in Burkina Faso, 
Togo and northern Ghana in the past25–28 and more recently in the Brong Ahafo Region of Ghana29. West African 
pneumococcal outbreaks have characteristically high case-fatality rates (up to 40%) and appear to mimic menin-
gococcal meningitis outbreaks. Although pneumococcus accounted for only 5% of confirmed cases in this out-
break, this finding highlights the need for surveillance and monitoring pneumococcal invasive disease in Nigeria.
An important limitation of this study is that only a very small proportion (6%) of the 7140 suspected cases had 
lumbar puncture performed and an even smaller fraction (5%) were tested in the laboratory. In addition, highly 
sensitive quantitative PCR testing was not performed on nearly half of the CSF specimens collected (Fig. 1). As a 
consequence, we probably missed a significant number of positive specimens. The meningococcal isolates were 
lost due to poor storage conditions in Zamfara state, therefore more extensive antibiotic resistance and genomic 
characterisation of the strains was not performed. Genotyping by MLST of the strains had to be performed 
directly from CSF specimens and this could only be done for two specimens due to limited funds. This report 
would have been enriched by the inclusion of more detailed clinical and vaccination history data of the suspected 
meningitis cases. For instance, we could not assess the clinical features such as meningococcaemia that could be 
associated with high mortality. Unfortunately, clinical and demographic data were not recorded routinely among 
suspected meningitis cases.
The NmC outbreak in Zamfara with over 500 hundred deaths is strong evidence of the on-going expansion 
of NmC epidemics. To curtail the spread of NmC outbreaks, governments and partner agencies should consider 
investing in targeted vaccination of the most vulnerable children (5–14 years old) and communities. However, 
sustainable control and elimination of meningitis outbreaks in the Africa meningitis belt may depend on the 
extension of the highly successful preventive MenAfriVac campaign framework to include multivalent conjugate 
meningococcal vaccine that covers the serogroups with the potential to cause outbreaks7,30. Licensed NmC con-
jugate vaccines remain largely unaffordable to countries facing the biggest risk of outbreaks. A polyvalent vaccine 
containing serogroups C and X conjugates has been developed by the Serum Institute of India and is currently 
undergoing clinical trials in Mali31. As the threat of large meningitis outbreaks looms with every harmattan sea-
son, a global action plan that will mobilise resources is urgently needed to strengthen surveillance and prepared-
ness systems in Africa. Without such an action plan, it is likely that many more lives will be lost.
Materials and Methods
Study Area. Zamfara State is located in North-western Nigeria and has an estimated population of 3.85 mil-
lion. The largest referral hospital, Ahmad Sani Yariman Bakura Specialist Hospital Gusau is in the state capital, 
Gusau. The state is divided into fourteen LGA. All LGAs, between December 2016 and May 2017, reported sus-
pected meningitis cases. Zamfara has a Sahel Climate, mostly hot and dry, with temperatures rising as high as 
40 °C between March and May. The Harmattan, hot and dry winds, lasts from February until the onset of the rains 
in June.
Case definitions. Suspected meningitis was defined as sudden onset of fever (>38 °C) in combination with 
stiff neck, altered consciousness and/or petechial rash among patients older than one year. Among infants, sus-
pected meningitis was defined as sudden onset of fever with bulging fontanel and/or petechial rash. Cerebrospinal 
fluid (CSF) was collected from suspected meningitis patients. Patients with suspected meningitis were treated 
with ceftriaxone as recommended by WHO17. Cerebrospinal fluid (CSF) was collected from patients meeting the 
case definition. Suspected cases were reported to the LGA and the State Disease Surveillance Team (DST).
Bacteriologic analysis of CSF specimens. For bacteriologic analysis, 0.5–1.0 ml of patients’ CSF spec-
imen were inoculated upon collection into each of Trans-Isolate (TI) medium when available, a plain tube and 
a calcium oxalate bottle and transported to the Ahmed Sani Yariman Bakura Specialist Hospital, Gusau within 
24 hours. Upon arrival in the laboratory, an aliquot of the CSF specimen was centrifuged at 1,000 × g for 10 min-
utes and the supernatant was boiled for three minutes at 100 °C, cooled and used for Pastorex according to man-
ufacturer’s instructions. The sediment was inoculated onto a plate 5% sheep blood agar and chocolate agar and 
used to prepare a smear for gram stain. White blood cell (WBC) count and CSF protein testing were done from 
the plain tube, and CSF glucose tested using the calcium oxalate samples. The improved Neubauer counting 
chamber was used for the WBC counts.
Following overnight incubation at 37 °C and in 5% CO2, media plates were examined for growth character-
istic of pneumococcus, Haemophilus influenzae and meningococcus. Alpha-haemolytic colonies were subjected 
to optochin (5 μg) testing; and smooth, glistening and moist colonies positive for the oxidase test subjected to 
Analytical Profile Index (API; BioMérieux SA, France) for confirmation as pneumococcus and meningococcus, 
respectively.
Serotyping of pneumococcal isolates was done using the latex agglutination method developed at MRCG 
as described previously32. Meningococcal serogroups were confirmed by slide latex agglutination serogrouping 
using Pastorex (Bio-Rad, UK) according to manufacturer’s protocol33.
Molecular detection and serotyping. Molecular detection of pneumococcus, H. influenzae and menin-
gococcus in CSF specimens was performed at the NCDC Laboratory, Abuja, Nigeria as previously described29. All 
CSF specimens analysed were also subjected to an RNaseP gene assay to confirm they were of human origin and 
to ascertain the integrity of the nucleic acids in the specimens. Specimens positive for H. influenzae and menin-
gococcus were serotyped/serogrouped as previously described29.
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CSF specimens positive for pneumococcus were shipped to the WHO CC at MRCG for molecular pneumo-
coccal serotyping using the African scheme as described previously34. CSF specimens with CT values >32 were 
further subjected to conventional multiplex PCRs also described elsewhere35,36.
Meningococcal Genotyping. MLST PCRs were carried out directly on only two of the CSF specimens that 
tested positive for NmC as previously described37,38. More specimens could not be tested due to limited funds. 
Nucleic acids were sent to Macrogen, Amsterdam Netherlands for amplification and sequencing of the seven 
housekeeping genes (abcZ, adk, aroE, fumC, gdh, pdhC and pgm).
Data collection and analysis. Data collection was carried out using a customized version of the WHO 
immediate case-based report Integrated Disease Surveillance Report (IDSR) form and the Invasive Bacterial 
Vaccine Preventable Disease (IB-VPD) surveillance excel line list template. Demographic and clinical data were 
entered into the Microsoft Excel WHO approved IB-VPD surveillance line list template at the first reporting 
health facility. The completed ward line lists were collated and verified by the LGA by Disease Surveillance 
Notification Officers (DSNO) who in turn reported to the State Disease Surveillance Office. All CSF specimens 
were accompanied with a completed case-based report form in which laboratory results were appended. The 
Excel data sets from all LGAs were imported and merged into a Microsoft Access database. Pathogen detection 
and serotyping data were imported and merged with demographic and clinical data in the customised Microsoft 
Access database. Geographical Position System (GPS) coordinates of the Zamfara government levels (federal, 
state and LGAs) areas were downloaded from the United States of America Geographical Survey ((USGS), 
https://www.usgs.gov). Data analysis was carried out using R statistics tool (version 3.3.1) and Microsoft Excel. 
The maps were generated using QGIS v2.18.
A logistic regression model was applied to estimate odds ratios and their 95% confidence intervals for the 
associations between mortality and potential risk factors including age, timing (week) of disease onset and LGA 
of suspected cases. Sex was used as predefined potential confounder in the model. All analyses were carried out 
using Stata/SE 14.1 (Stata Corp. Texas, USA). P-values < 0.05 have been taken to indicate statistical significance.
Ethics approval and consent to participate. All cases of suspected meningitis were defined following 
WHO protocol. The study was approved by the scientific coordinating committee of MRC Unit The Gambia and 
the joint MRC Unit/Gambian Government Ethics Committee (reference number SCC1188). All surveillance 
participants including parents/guardians of all children gave informed consent prior to enrolment.
The MRC Unit The Gambia, molecular microbiology laboratory submits to the external quality assurance 
programme of the UK National External Quality Assessment Service (http://www.ukneqas.org.uk) and is a World 
Health Organization (WHO) Regional Reference Laboratory for invasive bacterial pathogens.
All the methods in this study, including clinical and laboratory were carried out using WHO protocols.
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